This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

16 Nov 2011

FDA Nods for Cord Blood Therapy

The FDA has approved Hemacord for the treatment of blood forming disorders or cancer.

The US FDA has approved the first hematopoietic progenitor cells-cord (HPC-C) cell therapy for the treatment of blood forming disorders or cancer.


Hemacord manufactured by the New York Blood Center uses cells of human blood from the placenta and the umbilical cord to treat patients with certain blood cancers and some inherited metabolic and immune system disorders.


Cord blood is one of three sources of HPCs used in transplants, the other two are bone marrow and peripheral blood, the flowing blood that circulates through the body. Once these HPCs are infused into patients, the cells migrate to the bone marrow where they divide and partially or fully restore the number and function of many blood cells, including immune function.

Related News